Nuvectis Pharma, Inc. (NVCT)
Oxford Ledge is still expanding full research coverage of NVCT. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Nuvectis develops NXP900, a precision cancer medicine targeting SRC and YES1 kinases, currently in Phase 1b clinical trials.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-06-30
- 8-K Other material event 2026-06-29
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-06-23
- 8-K Shareholder vote results 2026-06-12
- 10-Q Quarterly financial report (unaudited) 2026-05-05
Source: SEC EDGAR.
Annual results
5 years of annual figures for NVCT, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$26.4M | -$1.32 |
| 2024 | — | -$19.0M | -$1.11 |
| 2023 | — | -$22.3M | -$1.43 |
| 2022 | — | -$19.1M | -$1.51 |
| 2021 | — | -$12.9M | -$3.02 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for NVCT. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NVCT in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.